Akero Q1 2024 Earnings Report
Key Takeaways
Akero Therapeutics reported first quarter financial results, highlighting significant advancements in the clinical development of EFX and a strong cash position of over $900 million, expected to fund operations into the second half of 2027.
Reported statistically significant week 96 results from the Phase 2b HARMONY study of EFX in patients with pre-cirrhotic MASH.
Phase 3 SYNCHRONY Histology and SYNCHRONY Real-World studies in patients with pre-cirrhotic MASH (F2-F3) continue to enroll.
SYNCHRONY Outcomes study in patients with compensated cirrhosis due to MASH (F4) on track to be initiated in second quarter of 2024.
Cash, cash equivalents, and short-term marketable securities totaled $903.7 million as of March 31, 2024.
Akero
Akero
Forward Guidance
Akero believes that its current cash, cash equivalents, and short-term marketable securities will be sufficient to fund its Phase 3 SYNCHRONY Histology and Real-World studies through their respective primary endpoints and Akero’s current operating plan into the second half of 2027.